DUBLIN--(BUSINESS WIRE)--The "Nuclear Medicine/Radiopharmaceuticals Market to 2027 - Global Analysis and Forecasts by Applications; End User and Geography" report has been added to ResearchAndMarkets.com's offering.
The global nuclear medicine/radiopharmaceuticals market is expected to reach US$ 6,683.99 Mn in 2027 from US$ 3,982.11 Mn in 2018. The market is estimated to grow with a CAGR of 6.2% from 2019-2027.
The market for nuclear medicine/radiopharmaceuticals is expected to grow, owing to factors such as rising prevalence of chronic diseases, alpha radioimmunotherapy-based targeted oncology treatment, and advancements in imaging technologies using radiopharmaceuticals.
However, the restraints, such as short shelf-life of radiopharmaceuticals and availability of substitutes of radiopharmaceuticals, are likely to impact the growth of the market in the forecast period.
The shelf-life or expiry date of a radiopharmaceutical preparation depends mainly on the half-life of the radioisotope, the radiochemical stability and the content of longer-lived radionuclide impurities in the preparation under consideration. Most of the radiopharmaceutical preparations contain radioisotopes with very short half-lives and such preparations have very short shelf-lives.
These preparations require an expiry date and time to be indicated. For example, technetium based preparations and positron emission tomography (PET) preparations are generally intended to be used within less than 12 hours, or sometimes within few minutes of preparation. Hence, the short shelf-life of radiopharmaceuticals are expected to hinder the growth of the market in the future years.
Global nuclear medicine/radiopharmaceuticals were segmented by application and end user. The application segment was segmented as diagnostic applications and therapeutic applications. Based on the end user, the market was segmented as hospitals and diagnostic centers. During 2018, the hospitals segment led the nuclear medicine/radiopharmaceuticals market by the end user.
Some of the major primary and secondary sources included in the report for, Society of Nuclear Medicine, Food and Drug Administration, American Cancer Society, World Health Organization, American Hospital Association (AHA), National Cancer Institute (NCI), Canadian Association of Nuclear Medicine, and others.
Key Topics Covered
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Global Nuclear Medicine/Radiopharmaceuticals Market - By Applications
1.3.2 Global Nuclear Medicine/Radiopharmaceuticals Market - By End User
1.3.3 Global Nuclear Medicine/Radiopharmaceuticals Market - By Geography
2. Global Nuclear Medicine/Radiopharmaceuticals Market - Key Takeaways
3. Research Methodology
3.2 Secondary Research
3.3 Primary Research
4. Global Nuclear Medicine/Radiopharmaceuticals Market - Market Landscape
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East & Africa PEST Analysis
4.2.5 South & Central America PEST Analysis
5. Global Nuclear Medicine/Radiopharmaceuticals market - Key Industry Dynamics
5.1 Key Market Drivers
5.1.1 Rising Prevalence of Chronic Diseases
5.1.2 Alpha Radioimmunotherapy-Based Targeted Oncology Treatment
5.1.3 Advancement in Imaging Technologies using Radiopharmaceuticals
5.2 Key Market Restraints
5.2.1 Short Shelf-Life of Radiopharmaceuticals
5.2.2 Availability of Substitutes of Radiopharmaceuticals
5.3 Key Market Opportunities
5.3.1 Development in the Healthcare Market
5.3.2 High Market Potential in Emerging Nations
5.4 Current Trend
5.4.1 Use of Nuclear Medicine For Personalized Treatment
5.5 Impact Analysis
6. Nuclear Medicine/Radiopharmaceuticals Market - Global Analysis
6.1 Global Nuclear Medicine/Radiopharmaceuticals Market Revenue Forecasts and Analysis
6.2 Global Nuclear Medicine/Radiopharmaceuticals Market, By Geography - Forecasts and Analysis
6.3 Performance/ Positioning of Key Players
6.3.1 Cardinal Health
6.3.2 General Electric
7. Global Nuclear Medicine/Radiopharmaceuticals Market Analysis - by Applications
7.2 Global Nuclear Medicine/Radiopharmaceuticals Market by applications, 2018 & 2027 (%)
7.3 Diagnostic Applications Market
7.4 Therapeutic Applications Market
8. Global Nuclear Medicine/Radiopharmaceuticals Market Analysis - by End User
8.2 Global Nuclear Medicine/Radiopharmaceuticals Market, by End User 2018 & 2027 (%)
8.3 Hospitals market
8.4 Diagnostic Centers Market
9. Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 - Geographical Analysis
9.1 North America Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027
9.2 Europe Nuclear Medicine/Radiopharmaceuticals market Revenue and Forecasts to 2027
9.3 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027
9.4 Middle East & Africa Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027
9.5 Middle East & Africa Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
9.6 South and Central America Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027
10. Nuclear Medicine/Radiopharmaceuticals Market - Industry Landscape
10.2 Comparative Company Analysis
10.3 Growth Strategies done by the companies in the Market, (%)
10.4 Organic Developments
10.5 Inorganic developments
11. Nuclear Medicine/Radiopharmaceuticals Market - Key Company Profiles
11.1 Cardinal Health
11.2 General Electric (GE)
11.3 IBA Worldwide
11.5 Positron Corporation
11.6 Lantheus Medical Imaging Inc.
11.7 NTP Radioisotopes SOC Ltd. (Necsa)
11.8 BAYER AG
11.10 Advanced Accelerator Applications (Novartis AG)
For more information about this report, visit https://www.researchandmarkets.com/r/4ocsx6.